Replies to post #267119 on Avid Bioservices Inc (CDMO)

[cheynew]

Here it is:

http://myeloidsuppressors.com/

[volgoat]

lol, probably made up.

MDSC's are far from being proven in Human's so not many in Biotech are wasting their time on this after 30 years.

Again, if you cant cure mice, you are in the wrong business.

PPHM probably paid some co's to attend.

[biopharm]

North, lots of puzzle pieces here. Not mentioned much at all would be Robert A. Weinberg...though his ties to Broad Institute and all those T101 posts re: Broad Institute now makes me go back and start searching again...I will start with the red highlighted below

Keynote Presentation

Robert A. Weinberg, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA

Confirmed Speakers

Scott Abrams, Roswell Park Cancer Institute, Buffalo, NY

Ron N. Apte, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Fotis Asimakopoulos, University of Wisconsin, Madison, WI

Michal Baniyash, The Hebrew University of Jerusalem, Jerusalem, Israel

Bruce R. Blazar, University of Minnesota, Minneapolis, MN

Ivan M. Borrello, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Sven Brandau, University Hospital Essen/West German Cancer Center, Essen, Germany

Rolf A. Brekken, University of Texas Southwestern Medical Center, Dallas, TX

Vincenzo Bronte, University of Verona, Verona, Italy

Shu-Hsia Chen, Ichan School of Medicine at Mt. Sinai, New York, NY

Mario Colombo, Italian National Cancer Institute, Milan, Italy

José R. Conejo-Garcia, The Wistar Institute, Philadelphia, PA

Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, NY

David G. DeNardo, Washington University School of Medicine, St. Louis, MO

Evgeniy B. Eruslanov, University of Pennsylvania, Philadelphia, PA

Zvi G. Fridlender, Hadassah Medical Center, Jerusalem, Israel

Dmitry I. Gabrilovich, The Wistar Institute, Philadelphia, PA

Tim F. Greten, Center for Cancer Research, NCI, Bethesda, MD

Rosandra Kaplan, Center for Cancer Research, NCI, Bethesda, MD

Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden

Marcin Kortylewski, City of Hope Comprehensive Cancer Center, Duarte, CA

Vinit Kumar, The Wistar Institute, Philadelphia, PA

Ming O. Li, Memorial Sloan Kettering Cancer Institute, New York, NY

Alberto Mantovani, Humanitas Clinical and Research Center, Milan, Italy

Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY

Luis J. Montaner, The Wistar Institute, Philadelphia, PA

David H. Munn, Georgia Regents University Cancer Center, Augusta, GA

Peter J. Murray, St. Jude Children’s Research Hospital, Memphis, TN

Yulia Nefedova, The Wistar Institute, Philadelphia, PA

Augusto Ochoa, Stanley S. Scott Cancer Center, Louisiana State University School of Medicine, New Orleans, LA

Suzanne Ostrand-Rosenberg, University of Maryland, Baltimore, MD

Graham Pawelec, Center for Medical Research, University of Tübingen, Tübingen, Germany

Mikael J. Pittet, Massachusetts General Hospital, Harvard University, Boston, MA

Jeffrey W. Pollard, The University of Edinburgh, Edinburgh, United Kingdom

Sophia Ran, Southern Illinois University, Springfield, IL

Paulo C. Rodriguez, Georgia Regents University Cancer Center, Augusta, GA

Mikael Roussel, Vanderbilt University, Nashville, TN and University Hospital, Rennes, France

Paolo Serafini, University of Miami, Miami, FL

Michael Shurin, University of Pittsburgh School of Medicine, Pittsburgh, PA

Antonio Sica, Humanitas Clinical and Research Center, Milan, Italy

Viktor Umansky, German Cancer Research Center, Heidelberg, Germany

William van der Touw, Ichan School of Medicine at Mount Sinai, New York, NY

Jo Van Ginderachter, Vrije Universiteit Brussels, Brussels, Belgium

Jeffrey S. Weber, NYU Langone Medical Center, New York, NY

Sheng Wei, H. Lee Moffit Cancer Center, Tampa, FL

Li Yang, Center for Cancer Research, NCI, Bethesda, MD

Jie Zhou, Sun Yet-Sen University, Guangzhou, China

Weiping Zou, University of Michigan, Ann Arbor, MI

http://myeloidsuppressors.com/speakers/

http://myeloidsuppressors.com/program/

What surprise from left field will come next? All this is not really coming from left field, it only seems that way because the puzzle pieces have been left out in the open for so long with no one talking ... and connecting the dots publicly to PS Targeting. Now, this may signal the start of lots of talking and damn, volgoat was right.... its all happening after the closure of the CA : )